• TriSalus Life Sciences Inc TLSI.OQ reported a quarterly adjusted loss of 39 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -60 cents. The mean expectation of seven analysts for the quarter was for a loss of 22 cents per share. Wall Street expected results to range from -30 cents to -9 cents per share.

• Revenue rose 42% to $9.17 million from a year ago; analysts expected $9.04 million.

• TriSalus Life Sciences Inc's reported EPS for the quarter was a loss of 39 cents​.

• The company reported a quarterly loss of $11.09 million.

• TriSalus Life Sciences Inc shares had fallen by 11.2% this quarter and lost 2.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.6% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $11.00

This summary was machine generated from LSEG data May 15 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)